Vilon
About
About Vilon
Vilon is a dipeptide (Lys-Glu) bioregulator developed in Russia targeting thymus and immune function, proposed to restore immune competence in aging and immunocompromised individuals. It has been studied in Russian clinical settings for immune modulation, anti-aging, and as adjunct therapy in chronic disease. Like other bioregulator peptides, it is thought to act by restoring normal gene expression in target tissues.
Science
Mechanism of Action
Proposed thymus-targeting dipeptide that interacts with nuclear chromatin to normalize gene expression in thymocytes and peripheral immune cells, potentially restoring thymic output and T-cell repertoire diversity that declines with age.
Dosing
Typical Protocol
1–2 mg subcutaneous injection daily for 10-day cycles; limited standardized dosing data available.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
No verified providers offering Vilon yet
We audit new providers every week. Leave your email and we’ll let you know as soon as a Vial-verified provider starts offering Vilon.
Free. We’ll only email when there’s a real match.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.